title: Renal vasodilation with ureteral occlusion and prostaglandins: attenuation by histamine H1 antagonists.
abstract: We evaluated the effects of histamine receptor antagonists on the renal vasodilatory responses to ureteral occlusion (UO), to the intrarenal infusion of prostaglandins E2, I2, A2, D2 and E1, and to bradykinin. We also determined the effects of meclofenamic acid, a cyclooxygenase inhibitor, on histamine-induced renal vasodilation and the effects of 2-methylhistamine (2-MeH), and H1 agonist, on glomerular filtration rate (GFR) and renal blood flow (RBF). Experiments were performed on adult mongrel dogs anesthetized with pentobarbital sodium. RBF was measured with an electromagnetic flow probe. Neither UO-induced nor prostaglandin- (PG) induced renal vasodilation was affected by infusion of the histamine H2 receptor antagonist cimetidine into the renal artery at 10(-5) M/min. On the other hand, renal artery infusion of the H1 receptor antagonist chlorpheniramine (CP) at 10(-5) M/min blocked UO-induced renal vasodilation [RBF increased 34 +/- 4% (SE) prior to but only 2 +/- 2% during infusion of CP) and markedly attenuated PGI2-, PGA2-, and PGE2-induced increases in RBF (CP inhibited 64 +/- 9% of the PGE2-induced renal vasodilation). CP had less effect on the renal vasodilation associated with infusion of PGD2 or PGE1 and had no effect on the vasodilation induced by bradykinin. Infusion of exogenous histamine (1 micrograms X kg-1 X min-1) into the renal artery prior to ureteral occlusion resulted in a typical H1 + H2-mediated vasodilatory response (RBF increased 53 +/- 7%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: R O
authors.initials: RO
authors.lastname: Banks
authors.forename: E D
authors.initials: ED
authors.lastname: Jacobson
mesh_terms: D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology; D002744:Chlorpheniramine / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D015232:Dinoprostone; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply*; D008297:Male; D008433:Mathematics; D008469:Meclofenamic Acid / Q000494:pharmacology; D008761:Methylhistamines / Q000494:pharmacology; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000494:pharmacology*; D011454:Prostaglandins A / Q000494:pharmacology; D011457:Prostaglandins D / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014513:Ureter / Q000502:physiology*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D006634:Histamine H1 Antagonists; D008761:Methylhistamines; D011453:Prostaglandins; D011454:Prostaglandins A; D011457:Prostaglandins D; D011458:Prostaglandins E; D002744:Chlorpheniramine; D008469:Meclofenamic Acid; D002927:Cimetidine; D011464:Epoprostenol; D000527:Alprostadil; C026259:2-methylhistamine; D011738:Pyrilamine; C100008:prostaglandin A2; D015232:Dinoprostone; D015230:Prostaglandin D2; D001920:Bradykinin